| 23 -5.213 (-18.48%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 38.54 | 1-year : | 49.19 |
| Resists | First : | 33 | Second : | 42.11 |
| Pivot price | 23.63  |
|||
| Supports | First : | 18.25 | Second : | 15.18 |
| MAs | MA(5) : | 27.48 |
MA(20) : | 22.33 |
| MA(100) : | 10.22 |
MA(250) : | 9.11 |
|
| MACD | MACD : | 3.8 |
Signal : | 3.8 |
| %K %D | K(14,3) : | 35.8 |
D(3) : | 40.3 |
| RSI | RSI(14): 53.4 |
|||
| 52-week | High : | 42.11 | Low : | 3.65 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ APLM ] has closed above bottom band by 47.4%. Bollinger Bands are 336.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 27.01 - 27.17 | 27.17 - 27.33 |
| Low: | 22.27 - 22.42 | 22.42 - 22.58 |
| Close: | 22.72 - 22.98 | 22.98 - 23.26 |
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
Wed, 15 Oct 2025
Apollomics Inc. Secures Continued Listing on Nasdaq Following Compliance Determination - Quiver Quantitative
Wed, 15 Oct 2025
Nasdaq Resumes Trading in Apollomics Inc. - The Manila Times
Wed, 15 Oct 2025
Nasdaq Cancels Hearing; Apollomics to Remain Listed After Staff Finds Compliance on Oct. 14, 2025 - Stock Titan
Wed, 15 Oct 2025
Apollomics Inc. Secures Continued Listing on Nasdaq Following Compliance Notification - Quiver Quantitative
Wed, 15 Oct 2025
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation - Sahm
Tue, 14 Oct 2025
Trading Resumes Oct. 15 for Apollomics Shares and Warrants; Trading Halted Sept. 17 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 542080 (%) |
| Held by Institutions | 105.6 (%) |
| Shares Short | 15 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.105e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 1 % |
| Return on Assets (ttm) | 7.3 % |
| Return on Equity (ttm) | -75.1 % |
| Qtrly Rev. Growth | 198000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -126.31 |
| EBITDA (p.s.) | 107027 |
| Qtrly Earnings Growth | -52.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.19 |
| Price to Cash Flow | 9.64 |
| Dividend | 0 |
| Forward Dividend | 75480 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|